Interstitial Lung Disease Spotlight

Availability

On-Demand

Access expires on 12/30/2024

Credit Offered

10 CME / CE Credits

10 MOC Points

10 RN Credits

10 PA Credits

10 AANPCB Credits

The Interstitial Lung Disease Spotlight content addresses a number of timely topics including emerging diagnostic technologies, distinguishing among and selecting treatment for various ILDs, updates on both pharmacological and nonpharmacological treatment and management options, and management of ILD post-COVID.

Determine which patient’s interstitial lung disease warrants further evaluation with a different diagnostic modality.
Apply multidisciplinary and interprofessional strategies to evaluate and manage patients with various forms of ILD.
Discuss advances in treatment of associated entities and/or complications, in cases of CTD-ILD, such as pulmonary arterial hypertension.
Recognize a patient presenting with an ILD with a progressive phenotype.
Identify the key prevalence and key clinical manifestations of extrapulmonary sarcoidosis.
Identify the reported types of interstitial lung abnormalities found on CT scans after COVID-19.
Identify radiographic features suggestive of developing a progressive fibrotic lung disease.
Identify additional oxygen provision therapies beyond oxygen concentrators and liquid oxygen devices, including transtracheal oxygen, home high-flow nasal cannula, and oxymizers.
Define treatment strategy, timing of escalation of treatment, and approach to steroid refractory immune checkpoint inhibitor pneumonitis.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and by an educational grant from Genentech, a member of the Roche group.